← 返回

新型 CRISPR 工具在脑部治疗中的应用

英文原题:Application of novel CRISPR tools in brain therapy.

查看英文原题

Application of novel CRISPR tools in brain therapy.

PubMed 2024/06/20(内容时间) Life Sci Q1 · IF 6.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

近年来,基于成簇规律间隔短回文重复序列(CRISPR)的基因组编辑工具包已被广泛用于修饰生物体的基因组序列。随着CRISPR工具箱的不断扩展以及新的CRISPR相关(Cas)蛋白被发现,其应用已超越传统的基因组编辑。如今,这涵盖了表观遗传编辑、基因表达调控以及多种其他功能。

值得注意的是,这些进展正在脑部疾病的治疗中找到实际应用。此外,CRISPR与CAR-T 细胞技术的结合已成为一种潜在的疾病治疗方法。有鉴于此,本综述首先全面概述CRISPR基因编辑工具的最新进展。这包括对各种Cas蛋白、基因表达调控、表观遗传编辑、碱基编辑和引物编辑的探讨。

此外,我们深入审视了这些创新CRISPR工具在脑部治疗领域的多方面应用,如神经退行性疾病、神经系统综合征和遗传性疾病、癫痫性疾病以及脑肿瘤,并探讨了这些疾病的发病机制。这包括它们在建模、基因筛选、治疗性基因编辑中的应用,以及它们与CAR-T 技术新兴的协同作用。

最后,我们讨论了在疾病治疗中有效利用CRISPR工具仍需解决的剩余技术挑战。

展开英文摘要原文

In recent years, the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based genome editing toolkit has been widely used to modify the genome sequence of organisms. As the CRISPR toolbox continues to grow and new CRISPR-associated (Cas) proteins are discovered, its applications have expanded beyond conventional genome editing. This now encompass epigenetic editing, gene expression control, and various other functions.

Notably, these advancements are finding practical application in the treatment of brain diseases.

Furthermore, the amalgamation of CRISPR and Chimeric Antigen Receptor T-cell (CAR-T) technologies has emerged as a potential approach for disease treatment. With this in mind, this review commences by offering a comprehensive overview of recent advancements in CRISPR gene editing tools. This encompasses an exploration of various Cas proteins, gene expression control, epigenetic editing, base editing and primer editing.

Additionally, we present an in-depth examination of the manifold applications of these innovative CRISPR tools in the realms of brain therapeutics, such as neurodegenerative diseases, neurological syndromes and genetic disorders, epileptic disorders, and brain tumors, also explore the pathogenesis of these diseases. This includes their utilization in modeling, gene screening, therapeutic gene editing, as well as their emerging synergy with CAR-T technology.

Finally, we discuss the remaining technical challenges that need to be addressed for effective utilization of CRISPR tools in disease treatment.

论文信息

作者
Shang J、Song F、Zhang Z、Chen D、Yang S
第一作者单位
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China.China
通讯作者单位
School of Pharmaceutical Sciences, Zhengzhou University, Henan Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou 450001, China. Electronic address: senyang@zzu.edu.cn.China
文献类型
综述
期刊
Life sciences2024 Sep 1
原文标识
PubMed 38908787 · DOI 10.1016/j.lfs.2024.122855